Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796411 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL29234488 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL2181037 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL31109139 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL15264615 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL31015822 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL31015823 | 0.98 | GSTK1 (0.63) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL4799643 | 0.95 | GSTK1 (0.67) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL8876658 | 0.95 | GSTK1 (0.61) | GSTK1LMNANFKB1TSHRPMP22 | |
| SCHEMBL28812185 | 0.93 | FFAR1 (0.56) | GSTK1LMNANFKB1TSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
| EP-1216223-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | PC, GOT2, SDHA | GSTK1 3127/4885LMNA 2227/4885NFKB1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.